{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:23:15Z","timestamp":1787030595583,"version":"build-2736575974"},"reference-count":111,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2013,5]]},"abstract":"<jats:p>The detection and characterization of a large array of autoantibodies, including at least 8 different antisynthetase, anti-SRP, -200\/100 (HMGCR), -Mi-2, -CADM-140 (MDA5), -SAE, -p155, -MJ (NXP-2), and -PMS1, frequently associated with distinct and well-defined clinicopathological features, allowed for significant improvement in the definition and diagnosis of idiopathic inflammatory myopathies (IIM). Classification remains difficult, with lingering divergence between the different specialties involved in IIM care, but several categories clearly stand out, including dermatomyositis (DM), overlap myositis (OM), polymyositis, necrotizing myositis, and sporadic inclusion body myositis (s-IBM). Biopsy and histological analysis remain crucial, particularly in the absence of autoantibodies, to accurately specify the diagnosis and rule out mimics such as muscular dystrophies and metabolic myopathies. Numerous infectious agents (in particular human immunodeficiency virus and human T cell lymphotrophic virus-1) and drugs (statins, tumor necrosis factor inhibitors, and proton pump inhibitors) can cause mimic IIM that must also be excluded. Pharmacological treatment, in addition to glucocorticoids and immunoglobulins, now includes mycophenolate mofetil and rituximab, which proved helpful in resistant cases, particularly rituximab in DM and OM. Exercise, initially seen as potentially deleterious, recently was shown to be efficacious and safe. IIM can thus be reasonably well controlled in most cases, although aggressive disease remains refractory to treatment, including some cases of necrotizing myopathy. Sporadic IBM still seems resistant to all medications tested to date.<\/jats:p>","DOI":"10.3899\/jrheum.120682","type":"journal-article","created":{"date-parts":[[2013,3,16]],"date-time":"2013-03-16T03:42:35Z","timestamp":1363405355000},"page":"550-564","source":"Crossref","is-referenced-by-count":79,"title":["Classification, Diagnosis, and Management of Idiopathic Inflammatory Myopathies"],"prefix":"10.3899","volume":"40","author":[{"given":"Ilias N.","family":"Lazarou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Andr\u00e9","family":"Guerne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2013,3,15]]},"reference":[{"key":"2018112909313192000_40.5.550.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2018112909313192000_40.5.550.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80255-9"},{"key":"2018112909313192000_40.5.550.3","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000173991.74008.b0"},{"key":"2018112909313192000_40.5.550.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006"},{"key":"2018112909313192000_40.5.550.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.27704"},{"key":"2018112909313192000_40.5.550.6","doi-asserted-by":"publisher","DOI":"10.1186\/ar2276"},{"key":"2018112909313192000_40.5.550.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068502"},{"key":"2018112909313192000_40.5.550.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.040717"},{"key":"2018112909313192000_40.5.550.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.10.041"},{"key":"2018112909313192000_40.5.550.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.006"},{"key":"2018112909313192000_40.5.550.11","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20693"},{"key":"2018112909313192000_40.5.550.12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31827ebba1"},{"key":"2018112909313192000_40.5.550.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09274.x"},{"key":"2018112909313192000_40.5.550.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090549"},{"key":"2018112909313192000_40.5.550.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03216.x"},{"key":"2018112909313192000_40.5.550.16","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199905000-00001"},{"key":"2018112909313192000_40.5.550.17","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32833f1075"},{"key":"2018112909313192000_40.5.550.18","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834b324b"},{"key":"2018112909313192000_40.5.550.19","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.4.440"},{"key":"2018112909313192000_40.5.550.20","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1181-4"},{"key":"2018112909313192000_40.5.550.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2011.03.016"},{"key":"2018112909313192000_40.5.550.22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020266"},{"key":"2018112909313192000_40.5.550.23","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410380504"},{"key":"2018112909313192000_40.5.550.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70171-0"},{"key":"2018112909313192000_40.5.550.25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awr213"},{"key":"2018112909313192000_40.5.550.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780371206"},{"key":"2018112909313192000_40.5.550.27","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3283317b31"},{"key":"2018112909313192000_40.5.550.28","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10519"},{"key":"2018112909313192000_40.5.550.29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem088"},{"key":"2018112909313192000_40.5.550.30","doi-asserted-by":"publisher","DOI":"10.1097\/RMR.0b013e31825b2c35"},{"key":"2018112909313192000_40.5.550.31","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868438"},{"key":"2018112909313192000_40.5.550.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0318-5"},{"key":"2018112909313192000_40.5.550.33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2009.04390.x"},{"key":"2018112909313192000_40.5.550.34","doi-asserted-by":"publisher","DOI":"10.1007\/s00117-010-2106-6"},{"key":"2018112909313192000_40.5.550.35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2011.06016.x"},{"key":"2018112909313192000_40.5.550.36","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834bab42"},{"key":"2018112909313192000_40.5.550.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2010.01153.x"},{"key":"2018112909313192000_40.5.550.38","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2011.39"},{"key":"2018112909313192000_40.5.550.39","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.4.472"},{"key":"2018112909313192000_40.5.550.40","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410160207"},{"key":"2018112909313192000_40.5.550.41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.61.3.316"},{"issue":"Suppl 1","key":"2018112909313192000_40.5.550.42","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1212\/01.wnl.0000192260.33106.bb","article-title":"Inclusion-body myositis: Clinical, diagnostic, and pathologic aspects","volume":"2","author":"Engel","year":"2006","journal-title":"Neurology"},{"key":"2018112909313192000_40.5.550.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2006.08.005"},{"key":"2018112909313192000_40.5.550.44","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-200301000-00013"},{"key":"2018112909313192000_40.5.550.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2003.11.002"},{"key":"2018112909313192000_40.5.550.46","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075523"},{"key":"2018112909313192000_40.5.550.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.01.005"},{"key":"2018112909313192000_40.5.550.48","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2005.038455"},{"key":"2018112909313192000_40.5.550.49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keg427"},{"key":"2018112909313192000_40.5.550.50","doi-asserted-by":"publisher","DOI":"10.1002\/art.23963"},{"issue":"Suppl 61","key":"2018112909313192000_40.5.550.51","first-page":"S164","article-title":"Use of methotrexate in inflammatory myopathies","volume":"5","author":"Fendler","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909313192000_40.5.550.52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/art.1780240107","article-title":"Prednisone and azathioprine for polymyositis: Long-term followup","volume":"24","author":"Bunch","year":"1981","journal-title":"Arthritis Rheum"},{"issue":"Pt 1","key":"2018112909313192000_40.5.550.53","first-page":"824","article-title":"Guidelines of care for dermatomyositis. American Academy of Dermatology","volume":"5","author":"Drake","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"2018112909313192000_40.5.550.54","first-page":"207","article-title":"Survival in polymyositis: corticosteroids and risk factors","volume":"4","author":"Carpenter","year":"1977","journal-title":"J Rheumatol"},{"key":"2018112909313192000_40.5.550.55","first-page":"545","article-title":"Course of dermatomyositis-polymyositis: Comparison of untreated and cortisone-treated patients","volume":"43","author":"Winkelmann","year":"1968","journal-title":"Mayo Clin Proc"},{"key":"2018112909313192000_40.5.550.56","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2010.2"},{"key":"2018112909313192000_40.5.550.57","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90148-I"},{"key":"2018112909313192000_40.5.550.58","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)90344-3"},{"key":"2018112909313192000_40.5.550.59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.04.007"},{"key":"2018112909313192000_40.5.550.60","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.85"},{"key":"2018112909313192000_40.5.550.61","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-92-3-365"},{"key":"2018112909313192000_40.5.550.62","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.1.35"},{"key":"2018112909313192000_40.5.550.63","doi-asserted-by":"crossref","first-page":"814","DOI":"10.7326\/0003-4819-154-12-201106210-00009","article-title":"Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: A systematic review","volume":"154","author":"Booth","year":"2011","journal-title":"Ann Intern Med"},{"key":"2018112909313192000_40.5.550.64","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X"},{"key":"2018112909313192000_40.5.550.65","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh499"},{"key":"2018112909313192000_40.5.550.66","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel336"},{"key":"2018112909313192000_40.5.550.67","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000208416.32471.c0"},{"key":"2018112909313192000_40.5.550.68","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10026"},{"key":"2018112909313192000_40.5.550.69","first-page":"381","article-title":"Cyclosporine A as first choice therapy for dermatomyositis","volume":"21","author":"Grau","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909313192000_40.5.550.70","doi-asserted-by":"publisher","DOI":"10.3109\/03009749709065660"},{"key":"2018112909313192000_40.5.550.71","first-page":"707","article-title":"Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"23","author":"Ochi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909313192000_40.5.550.72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)01927-3"},{"key":"2018112909313192000_40.5.550.73","first-page":"2855","article-title":"Cyclosporin A in the treatment of refractory adult polymyositis\/dermatomyositis: Population based experience in 6 patients and literature review","volume":"27","author":"Qushmaq","year":"2000","journal-title":"J Rheumatol"},{"key":"2018112909313192000_40.5.550.74","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500124023"},{"key":"2018112909313192000_40.5.550.75","doi-asserted-by":"publisher","DOI":"10.1080\/030097400750001897"},{"key":"2018112909313192000_40.5.550.76","doi-asserted-by":"publisher","DOI":"10.1002\/art.21240"},{"key":"2018112909313192000_40.5.550.77","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S0140-6736(89)92416-1","article-title":"Cyclophosphamide in severe polymyositis","volume":"1","author":"Bombardieri","year":"1989","journal-title":"Lancet"},{"key":"2018112909313192000_40.5.550.78","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel112"},{"key":"2018112909313192000_40.5.550.79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"2018112909313192000_40.5.550.80","doi-asserted-by":"publisher","DOI":"10.1002\/art.10053"},{"key":"2018112909313192000_40.5.550.81","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0360"},{"key":"2018112909313192000_40.5.550.82","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-010-0298-2"},{"key":"2018112909313192000_40.5.550.83","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.6.635"},{"key":"2018112909313192000_40.5.550.84","doi-asserted-by":"publisher","DOI":"10.1159\/000070852"},{"key":"2018112909313192000_40.5.550.85","first-page":"1802","article-title":"Use of etanercept in the treatment of dermatomyositis: A case series","volume":"33","author":"Iannone","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909313192000_40.5.550.86","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh285"},{"key":"2018112909313192000_40.5.550.87","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh539"},{"key":"2018112909313192000_40.5.550.88","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048744"},{"key":"2018112909313192000_40.5.550.89","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22477"},{"key":"2018112909313192000_40.5.550.90","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077974"},{"key":"2018112909313192000_40.5.550.91","doi-asserted-by":"publisher","DOI":"10.1002\/art.20849"},{"key":"2018112909313192000_40.5.550.92","first-page":"1021","article-title":"Rituximab as therapy for refractory polymyositis and dermatomyositis","volume":"33","author":"Noss","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909313192000_40.5.550.93","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker305"},{"key":"2018112909313192000_40.5.550.94","doi-asserted-by":"publisher","DOI":"10.1002\/art.22856"},{"key":"2018112909313192000_40.5.550.95","first-page":"1864","article-title":"Rituximab for refractory polymyositis: An open-label prospective study","volume":"34","author":"Mok","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909313192000_40.5.550.96","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318190f170"},{"key":"2018112909313192000_40.5.550.97","doi-asserted-by":"publisher","DOI":"10.1002\/art.21332"},{"key":"2018112909313192000_40.5.550.98","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker292"},{"key":"2018112909313192000_40.5.550.99","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.3.712"},{"key":"2018112909313192000_40.5.550.100","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.2.326"},{"key":"2018112909313192000_40.5.550.101","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.7.1081"},{"key":"2018112909313192000_40.5.550.102","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2011.01501.x"},{"key":"2018112909313192000_40.5.550.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.09.016"},{"key":"2018112909313192000_40.5.550.104","doi-asserted-by":"publisher","DOI":"10.1002\/art.33403"},{"key":"2018112909313192000_40.5.550.105","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq153"},{"key":"2018112909313192000_40.5.550.106","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e3282f01a8c"},{"key":"2018112909313192000_40.5.550.107","doi-asserted-by":"publisher","DOI":"10.1002\/art.27572"},{"key":"2018112909313192000_40.5.550.108","first-page":"2230","article-title":"Polymyositis and dermatomyositis: Short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909313192000_40.5.550.109","first-page":"263","article-title":"Long-term prognosis of 69 patients with dermatomyositis or polymyositis","volume":"14","author":"Maugars","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909313192000_40.5.550.110","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.73.4.420"},{"key":"2018112909313192000_40.5.550.111","doi-asserted-by":"publisher","DOI":"10.1383\/medc.32.3.35.28615"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.120682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T13:26:38Z","timestamp":1543497998000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.120682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,15]]},"references-count":111,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,5,1]]},"published-print":{"date-parts":[[2013,5]]}},"alternative-id":["10.3899\/jrheum.120682"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.120682","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,15]]}}}